Regulation of Small Intestinal Transit by Central Nervous Calcitonin Receptor

Hamada, Shoko; Kawane, Takashi; Akeno, Nagako; Igarashi, Haruyoshi; Horiuchi, Noboru

doi:10.1055/s-2007-978783

Cited by 3 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intracerebroventricular injection of bombesin, 34 morphine, 65 clonidine 66 and salmon calcitonin 67 delayed small bowel transit in rodents. On the other hand, intracerebroventricular injection of GABA B agonist baclofen increased motility of the small intestine 68 .…”

Section: Introductionmentioning

confidence: 94%

Gastrointestinal motility and the brain‐gut axis

Ishiguchi

Itoh

Ichinose

2003

Digestive Endoscopy

View full text Add to dashboard Cite

The role of the brain‐gut axis in gastrointestinal motility is discussed according to the specific organs of the gastrointestinal tract. Not only clinical studies but basic animal research are reviewed. Although the mechanism of functional gut disorders remains to be clarified, recent data suggest that there is evidence that the brain‐gut axis has significant effects on gastrointestinal motility. The major role of endoscopy in the diagnosis of functional gastrointestinal disorders is to exclude organic gastrointestinal disorders. In the esophagus, the lower esophageal sphincter and a gamma‐aminobutyric acid B mechanism are considered to play important roles in gastroesophageal reflux disease. In the stomach, corticotropin‐releasing factor, neuropeptide Y and other substances might be involved in the pathogenesis of non‐ulcer dyspepsia. In the small intestine, corticotropin‐releasing factor, gamma‐aminobutyric acid B and other substances are considered to modulate intestinal transit via central mechanisms. In the colon, it is known that psychiatric factors are related to the onset and clinical course of irritable bowel syndrome. Serotonin, corticotropin‐releasing factor, gamma‐aminobutyric acid, orphanin FQ and neuropeptide Y have been reported as putative neurotransmitters. More efforts in basic science studies and animal and human studies of physiology of the gastointestinal tract are still required. These efforts will elucidate further mechanisms to clarify the etiology of motility disorders and encourage the investigation of new therapies in this field.

show abstract

Section: Introductionmentioning

confidence: 94%

Gastrointestinal motility and the brain‐gut axis

Ishiguchi

Itoh

Ichinose

2003

Digestive Endoscopy

View full text Add to dashboard Cite

show abstract

“…Twenty minutes after administration of the charcoal meal, the intestine was removed. The total length of the intestine, from duodenal end to the cecum, and the distance travelled by the charcoal were recorded and the percentage of charcoal movement was calculated (Hamada et al, 1999).…”

Section: Effect Of Sj-200 In Intestinal Transit Time In Micementioning

confidence: 99%

Antispasmodic Activity of SJ-200 (Himcospaz): An Herbal Preparation

Venkataranganna¹,

Anturlikar²,

Gopumadhavan³

et al. 2002

Pharmaceutical Biology

View full text Add to dashboard Cite

SJ-200 (Himcospaz), an herbal preparation, was investigated for antispasmodic activity on gastrointestinal smooth muscles of guinea pig, rats, rabbits and mice. SJ-200 dosedependently inhibited acetylcholine, histamine and barium chloride-induced contraction of guinea pig ileum. It inhibited spontaneous contraction of rabbit and rat colon. Oxytocin-induced contraction of rat uterus was also inhibited. Oral administration of SJ-200 dose-dependently reduced gastric emptying in rats and intestinal transit in mice. All these findings suggest the non-specific antispasmodic activity of SJ-200 in experimental models.

show abstract